Sickle cell disease related chronic thromboembolic pulmonary hypertension: challenging clinical scenario

被引:0
作者
Panagiotis Karyofyllis
Dimitrios Tsiapras
Eftychia Demerouti
Iakovos Armenis
Varvara Papadopoulou
Vassilis Voudris
机构
[1] Onassis Cardiac Surgery Center,Department of Interventional Cardiology
[2] Onassis Cardiac Surgery Center,Department of Non
来源
Journal of Thrombosis and Thrombolysis | 2022年 / 53卷
关键词
Sickle cell disease; Chronic thromboembolic pulmonary hypertension; Balloon pulmonary angioplasty; Endothelin receptor antagonist; Oral prostacyclin agonist;
D O I
暂无
中图分类号
学科分类号
摘要
Sickle cell disease (SCD), a haemoglobinopathy characterized by chronic haemolysis with acute exacerbations and vascular occlusion episodes, may be complicated by pulmonary hypertension. The latter may be caused by chronic thromboembolic disease of pulmonary artery branches and its management is not well-defined. Herein, we present a case of SCD complicated by chronic thromboembolic pulmonary hypertension of subsegmental pulmonary artery branches successfully treated with endothelin receptor antagonists, orally administered prostacyclin analogs and balloon pulmonary angioplasty. This challenging case highlights the need for clinical awareness of chronic thromboembolic pulmonary hypertension as a specific and potentially curable form of pulmonary hypertension complicating SCD course that may necessitate combined pharmacologic and interventional management.
引用
收藏
页码:467 / 470
页数:3
相关论文
共 78 条
[1]  
Simonneau G(2019)Haemodynamic definitions and updated clinical classification of pulmonary hypertension Eur Respir J 53 1801913-1256
[2]  
Montani D(2012)Mortality in adults with sickle cell disease and pulmonary hypertension JAMA 307 1254-53
[3]  
Celermajer DS(2011)A hemodynamic study of pulmonary hypertension in sickle cell disease N Engl J Med 365 44-1324
[4]  
Denton CP(2016)Chronic pulmonary complications of sickle cell disease Chest 149 1313-828
[5]  
Gatzoulis MA(2016)Pathophysiology and treatment of pulmonary hypertension in sickle cell disease Blood 127 820-740
[6]  
Krowka M(2014)An official american thoracic society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease Am J Respir Crit Care Med 189 727-516
[7]  
Mehari A(2005)Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension Thromb Haemost 93 512-847
[8]  
Gladwin MT(2013)Hemodynamic predictors of mortality in adults with sickle cell disease Am J Respir Crit Care Med 187 840-35
[9]  
Tian X(2010)Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies Br J Haematol 149 426-64
[10]  
Machado RF(2011)Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity Blood 118 855-e165